T cell activation alters intestinal structure and function

Journal of Clinical Investigation

Volumn 116, Issue 10, 2006, Pages 2580-2582

  Field, Michael ^a,b  

^a Columbia University ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; PROTEIN DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; WATER;

BRUSH BORDER; DIARRHEA; ENDOCYTOSIS; HUMAN; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; INTESTINE FLUID; INTESTINE FUNCTION; INTESTINE SECRETION; JEJUNUM; MEMBRANE PERMEABILITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SODIUM ABSORPTION; SOLUTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; BIOLOGICAL TRANSPORT; CAPILLARY PERMEABILITY; DIARRHEA; INTESTINAL MUCOSA; JEJUNUM; LYMPHOCYTE ACTIVATION; MICE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH; PERMEABILITY; SODIUM-HYDROGEN ANTIPORTER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR-ALPHA; WATER;

EID: 33749429032     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29985     Document Type: Review

References (16)

1. Ortho Multicenter Study Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313:337-341.
2. Radojevic, N., et al. 1999. Characterization of enteric functional changes evoked by in vivo anti-CD3 T cell activation. Am. J. Physiol. 276:R715-R723.
3. +-ATPase. J. Clin. Invest. 110:1739-1747. doi:10.1172/JCI200215695.
4. Clayburgh, D.R., et al. 2005. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J. Clin. Invest. 115:2702-2715. doi:10.1172/JCI24970.
5. Clayburgh, D.R., Musch, M.W., Leitges, M., Fu, Y.-X., and Turner, J.R. 2006. Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J. Clin. Invest. 116:2682-2694. doi:10.1172/JCI29218.
6. Brown, G.R., et al. 1999. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology. 116:593-601.
7. Bjarnson, I., et al. 1985. Intestinal permeability in patients with celiac disease and dermatitis herpetiformis. Gut. 26:1214-1219.
8. Yuhan, R., Koutsouris, A., Savkovic, S.D., and Hecht, G. 1997. Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology. 113:1873-1882.
9. Yachshyn, B.R., and Meddings, J.B. 1995. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology. 108:132-137.
10. Zolotarevsky, Y., et al. 2002. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology. 123:163-172.
11. Shen, L., et al. 2006. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J. Cell Sci. 119:2095-2106.
12. Field, M. 2003. Intestinal ion transport and the pathophysiology of diarrhea. J. Clin. Invest. 111:931-943. doi:10.1172/JCI200318326.
13. Schmitz, H., et al. 1996. Tumor necrosis factor-alpha induces Cl- and K+ secretion in human distal colon driven by prostaglandin E2. Am. J. Physiol. 271:G669-G674.
14. Yablonski, M.E., and Lifson, N. 1976. Mechanism of production of intestinal secretion by elevated venous pressure. J. Clin. Invest. 57:904-915.
15. Horvath, C.J., Ferro, T.J., Jesmok, G., and Malik, A.B. 1988. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc. Natl. Acad. Sci. U. S. A. 85:9219-9223.
16. Folli, S., et al. 1993. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int. J. Cancer. 53:829-836.